Health Care·Life Sciences Tools & Services·$8.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.34 | N/A | +0.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.34 | N/A | +0.44% |
| Revenue | N/A | N/A | N/A |
Tone: Confident
Overall, management conveyed a positive outlook on the company's performance. They emphasized their commitment to growth strategies.
Management expressed satisfaction with the EPS performance despite the lack of revenue data.
They highlighted ongoing initiatives to drive future growth.
Bio-Techne Corp's earnings report shows a solid EPS performance, which exceeded expectations and led to a positive stock reaction of 6.69%. The lack of revenue data leaves some uncertainty, but management's confidence suggests they are focused on future growth initiatives. Investors may view the EPS beat as a sign of resilience in the company's operations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WILLIS TOWERS WATSON
Aug 6, 2018